Fluorescence polarization binding assay to develop inhibitors of inactive p38α mitogen-activated protein kinase

Analytical Biochemistry

Volumn 401, Issue 1, 2010, Pages 125-133

  Munoz, Lenka ^a   Selig, Roland ^b   Yeung, Yiu To ^a   Peifer, Christian ^b   Hauser, Dominik ^b   Laufer, Stefan ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Binding assay; Fluorescence polarization; Inactive p38 MAPK

Indexed keywords

ADENOSINETRIPHOSPHATE; AMINO ACIDS; CHEMICAL ACTIVATION; DIAGNOSIS; ENZYME ACTIVITY; FLUORESCENCE; NEURODEGENERATIVE DISEASES; PLANTS (BOTANY);

ACTIVATION LOOPS; ALZHEIMER'S DISEASE; BINDING ASSAYS; FLUORESCENCE POLARIZATION; INHIBITOR SCREENINGS; KINASE INHIBITORS; LIVING CELL; MITOGEN ACTIVATED PROTEIN KINASE;

POLARIZATION;

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 14 INHIBITOR; N [3',6' DIHYDROXY 3 OXO 3H SPIRO(2 BENZOFURAN 1,9' XANTHEN) 4 YL] N' [4 [4 (4 FLUOROPHENYL) 5 PYRIDIN 4 YL 1H IMIDAZOL 2 YL]BENZYL]THIOUREA; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIDINYLIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 77951093267     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.02.016     Document Type: Article

References (35)

1. Ashwell J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 2006, 6:532-540.
2. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy: from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 2005, 1754:253-262.
3. Peifer C., Wagner G., Laufer S. New approaches to the treatment of inflammatory disorders with small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6:113-149.
4. Margutti S., Laufer S.A. Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem 2007, 2:1116-1140.
5. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568.
6. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., White R.F., McVey M.J., Legos J.J., Erhardt J.A., Nelson A.H., Ohlstein E.H., Hunter A.J., Ward K., Smith B.R., Adams J.L., Parsons A.A. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. 2001, 296:312-321.
7. Ji R.-R., Suter M. P38 MAPK, microglial signaling, and neuropathic pain. Mol. Pain 2007, 3:31-33.
8. Gaundar S.S., Bradstock K.F., Bendall L.J. P38 MAPk inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009, 8:2977-2985.
9. Chen L., Mayer J.A., Krisko T.I., Speers C.W., Wang T., Hilsenbeck S.G., Brown P.H. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009, 69:8853-8861.
10. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
11. Alton G.R., Lunney E.A. Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opin. Drug Discov. 2008, 3:595-605.
12. Okram B., Nagle A., Adrián F.J., Lee C., Ren P., Wang X., Sim T., Xie Y., Wang X., Xia G., Spraggon G., Warmuth M., Liu Y., Gray N.S. A general strategy for creating " inactive-conformation" Abl inhibitors. Chem. Biol. 2006, 13:779-786.
13. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., Tocci M.J., O'Keefe S.J., O'Neill E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998, 37:13846-13853.
14. Goldstein D.M., Alfredson T., Bertrand J., Browner M.F., Clifford K., Dalrymple S.A., Dunn J., Freire-Moar J., Harris S., Labadie S.S., La Fargue J., Lapierre J.M., Larrabee S., Li F., Papp E., McWeeney D., Ramesha C., Roberts R., Rotstein D., San Pablo B., Sjogren E.B., So O.-Y., Talamas F.X., Tao W., Trejo A., Villasenor A., Welch M., Welch T., Weller P., Whiteley P.E., Young K., Zipfel S. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J. Med. Chem. 2006, 49:1562-1575.
15. Leftheris K., Ahmed G., Chan R., Dyckman A.J., Hussain Z., Ho K., Hynes J., Letourneau J., Li W., Lin S., Metzger A., Moriarty K.J., Riviello C., Shimshock Y., Wen J., Wityak J., Wrobleski S.T., Wu H., Wu J., Desai M., Gillooly K.M., Lin T.H., Loo D., McIntyre K.W., Pitt S., Shen D.R., Shuster D.J., Zhang R., Diller D., Doweyko A., Sack J., Baldwin J., Barrish J., Dodd J., Henderson I., Kanner S., Schieven G.L., Webb M. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J. Med. Chem. 2004, 47:6283-6291.
16. Hynes J., Dyckman A.J., Lin S., Wrobleski S.T., Wu H., Gillooly K.M., Kanner S.B., Lonial H., Loo D., McIntyre K.W., Pitt S., Shen D.R., Shuster D.J., Yang X., Zhang R., Behnia K., Zhang H., Marathe P.H., Doweyko A.M., Tokarski J.S., Sack J.S., Pokross M., Kiefer S.E., Newitt J.A., Barrish J.C., Dodd J., Schieven G.L., Leftheris K. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38Îα mitogen-activated protein kinase inhibitors. J. Med. Chem. 2007, 51:4-16.
17. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Mol. Biol. 2002, 9:268-272.
18. Angell R.M., Angell T.D., Bamborough P., Bamford M.J., Chung C.-W., Cockerill S.G., Flack S.S., Jones K.L., Laine D.I., Longstaff T., Ludbrook S., Pearson R., Smith K.J., Smee P.A., Somers D.O., Walker A.L. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg. Med. Chem. Lett. 2008, 18:4433-4437.
19. Haile T., Frederic F., Hu L., Cyrille K., Glen R., Mark M., Jiangxing S., Alan C.C., Diana G., Juan M., Rocco C., Simon X., Susan L.C., Simon L., Steven K., Yuan-Hua D., Qing C., Theresa L.J., Gayatri D.D., Jonathan P.D., Joe C.W., Jessie M.E. The design, synthesis, and potential utility of fluorescence probes that target DFG-out conformation of p38α for high throughput screening binding assay. Chem. Biol. Drug Des. 2009, 74:547-559.
20. Simard J.R., Getlik M.U., Grütter C., Pawar V., Wulfert S., Rabiller M., Rauh D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J. Am. Chem. Soc. 2009, 131:13286-13296.
21. Sullivan J.E., Holdgate G.A., Campbell D., Timms D., Gerhardt S., Breed J., Breeze A.L., Bermingham A., Pauptit R.A., Norman R.A., Embrey K.J., Read J., VanScyoc W.S., Ward W.H.J. Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 2005, 44:16475-16490.
22. Bullington J., Argentieri D., Averill K., Carter D., Cavender D., Fahmy B., Fan X., Hall D., Heintzelman G., Jackson P., Leung W.-P., Li X., Ling P., Olini G., Razler T., Reuman M., Rupert K., Russell R., Siekierka J., Wadsworth S., Wolff R., Xiang B., Zhang Y.-M. Inhibitors of unactivated p38 MAP kinase. Bioorg. Med. Chem. Lett. 2006, 16:6102-6106.
23. Laufer S.A., Wagner G.K., Kotschenreuther D.A., Albrecht W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 2003, 46:3230-3244.
24. Ziegler K., Hauser D.R.J., Unger A., Albrecht W., Laufer S.A. 2-Acylaminopyridin-4-yl imidazoles as p38 MAP kinase inhibitors: design, synthesis, and biological and metabolic evaluations. ChemMedChem 2009, 4:1939-1948.
25. Laufer S.A., Hauser D.R.J., Domeyer D.M., Kinkel K., Liedtke A.J. Design, synthesis, and biological evaluation of novel tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. J. Med. Chem. 2008, 51:4122-4149.
26. Biftu T., Feng D., Ponpipom M., Girotra N., Liang G.-B., Qian X., Bugianesi R., Simeone J., Chang L., Gurnett A., Liberator P., Dulski P., Leavitt P.S., Crumley T., Misura A., Murphy T., Rattray S., Samaras S., Tamas T., Mathew J., Brown C., Thompson D., Schmatz D., Fisher M., Wyvratt M. Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents. Bioorg. Med. Chem. Lett. 2005, 15:3296-3301.
27. Wolkenberg S.E., Wisnoski D.D., Leister W.H., Wang Y., Zhao Z., Lindsley C.W. Efficient synthesis of imidazoles from aldehydes and 1,2-diketones using microwave irradiation. Org. Lett. 2004, 6:1453-1456.
28. Kim S.H., Smith C.J., Van Eldik L.J. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production. Neurobiol. Aging 2004, 25:431-439.
29. Dziembowska M., Danilkiewicz M., Wesolowska A., Zupanska A., Chouaib S., Kaminska B. Cross-talk between Smad and p38 MAPK signalling in transforming growth factor β signal transduction in human glioblastoma cells. Biochem. Biophys. Res. Commun. 2007, 354:1101-1106.
30. Da Silva J., Pierrat B., Mary J.-L., Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J. Biol. Chem. 1997, 272:28373-28380.
31. Li Y., Liu L., Barger S.W., Griffin W.S.T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
32. Munoz L., Ralay Ranaivo H., Roy S.M., Hu W., Craft J.M., McNamara L., Chico L., Van Eldik L.J., Watterson D.M. A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflamm. 2007, 4:21.
33. Kuma Y., Sabio G., Bain J., Shpiro N., Marquez R., Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 2005, 280:19472-19479.
34. Wang Z., Canagarajah B., Boehm J., Kassisa S., Cobb M., Young P., Abdel-Meguid S., Adams J., Goldsmith E. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6:1117-1128.
35. Martin V., Krishna S., Swen H., Susanne G., Marco B., Ulrich S., Barbara P., Michel R., Laure D., Thomas L., Wendt K.U., Harald S. NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew. Chem. Int. Ed. 2006, 45:993-997.